Eli Lilly and AC Immune have signed a license and collaboration agreement focussing on the R&D of tau aggregation inhibitor small molecules for the potential treatment of neurodegenerative diseases.
Officials from Angelina College and Stephen F. Austin State University on Tuesday met to perform a celebratory signing signaling the beginning of a new partnership designed to pave a clearer pathway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback